FDA Quality Of Life, Pharmacoeconomic Guidance Development On Hold
Executive Summary
FDA development of guidances for including quality of life claims in drug labeling and promotions and for formulary-directed pharmacoeconomic information is on hold until more information is collected.
You may also be interested in...
P&T Committees Would Be Powerful Force Under Medicare Rx
The recommendations of pharmacy & therapeutics committees would be binding on Medicare prescription drug plans under the proposed implementing regulations for the Part D benefit
P&T Committees Would Be Powerful Force Under Medicare Rx
The recommendations of pharmacy & therapeutics committees would be binding on Medicare prescription drug plans under the proposed implementing regulations for the Part D benefit
FDA Quality Of Life Guidance Receives Renewed Interest After Industry Input
FDA has renewed development of a guidance on the use of quality of life claims in drug labeling and promotional materials after gathering input from industry